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1. Introduction 
Breast cancer is one of the most common diseases and a major public health problem in the 
world today. It is responsible for 32% of all cancers and 15% of cancer deaths in women 
(Dirisamer et al., 2010). Advances in diagnosis and treatment of breast cancer have led to 
decline in mortality. However, just about 60% of patients can now be cured by initial 
treatments, but the rest, in spite of receiving palliation with currently available therapy 
methods die. Therefore, tremendous amounts of time and efforts are dedicated to search 
toward earlier detection and more efficient treatment of this disease. Advances in molecular 
cancer biology achieved an increased understanding of the biologic factors that contribute to 
breast cancer pathogenesis and progression. This understanding has already led to both 
early diagnosis and more effective treatment. Among different imaging and therapy 
contribution modalities, nuclear medicine provides an important role to the clinical 
management of breast cancer. In this chapter, we highlight the uses, advantages, limitations 
and possible improvements of radioimmunoscintigraphy and radioimmunotherapy 
techniques as targeted molecular imaging and therapy methods, respectively.  
2. Diagnosis of breast cancer 
Breast cancer is currently the most common cancer in females and the second highest cause 
of cancer death in female population of the world. The majority of breast cancer deaths are 
due to metastasis (Costelloe et al., 2009). If breast cancer is detected prior to metastatic 
spread, it has considerably better prognosis than the cancer that has already spread. 
Therefore, the detection of cancer in an early stage is a major factor in the reduction of 
patient mortality and leading to less cancer costs and more successful treatments. The 
management of patients with a suspicious lesion includes confirming the diagnosis, 
identifying the stage of disease and choosing an appropriate treatment for each individual 
patient. Identifying the stage of a disease in any patient is a crucial step, because it 
determines the type of treatment that is appropriate for that particular person. Also, it is 
necessary to follow patients that need therapeutic procedures to assess their response to the 
treatment. There are a number of methods available for the detection of breast cancer. This 
section briefly points out some difficulties that encounter with these conventional imaging 
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modalities and describes application of nuclear medicine techniques and targeted molecular 
imaging in the investigation of patients with breast cancer. 
2.1 Mammography 
Mammography is a gold standard imaging method for breast cancer screening, detection 
and diagnosis in women under forty with a relatively high sensitivity in the range of 85-90% 
(Berg et al., 2004). This method is a national screening program in the United Kingdom 
(Glasspool & Evans., 2000). Although mammography is an effective imaging tool, it is not 
without limitations like many other diagnostic modalities. First, the sensitivity of 
mammography decreases dramatically in young patients due to their dense breast tissues. 
On the other hand, its ability to detect malignant lesions in young female patients decreases 
to 68% (Nystrom et al., 2002, Kopans, 1992). As a result, some patients with breast cancer are 
missed and some others without a malignant tumor undergo unnecessary biopsies due to 
incorrect mammography findings. Secondly, mammography in patients evaluated following 
breast surgery or radiotherapy, is unreliable with a false negative rate of 25-45%, because it 
cannot always differentiate benign from malignant diseases (Fass, 2008). Many efforts have 
ever been taken to establish new tests to enable us to collect more complete information by 
non-invasive methods. These efforts minimize the use of breast biopsy in women who do 
not have breast cancer. Therefore, many other imaging modalities such as ultrasonography 
(US), magnetic resonance imaging (MRI), diffuse optical tomography (DOT), computed 
tomography (CT) and measurement of tumor markers in blood serum have been initiated to 
increase the diagnostic accuracy of mammography. 
2.2 Ultrasonography 
Ultrasonography is an important adjunct to mammography for both diagnosis and 
characterization of breast cancer and is routinely used in this role (Fass, 2009). It is non-
invasive, easily available, relatively cheap and also recommended for pregnant or lactating 
women when ionizing radiation may not be recommended (Schueller et al., 2008). It has 
been found that ultrasonography, when combined with mammography, can prevent up to 
22% of unnecessary biopsies (Zonderland, 2000). Although ultrasonography can reliably 
differentiate a cystic lesion from a solid lesion, it does not provide a high specificity to 
distinguish benign from malignant lesions (Balleyguier et al., 2008; Sauer et al., 2005). 
Another disadvantage of this method as a screening tool, when applied to general 
population, is low sensitivity and specificity and furthermore it is operator-dependent 
(Liberman, 2000).  
2.3 Magnetic Resonance Imaging (MRI) 
Breast cancer was one of the first that was examined using MRI (Ross et al., 1982). This 
method is very useful for further evaluation when mammography and ultrasonography are 
indeterminate to study the presence or location of a suspect abnormality (Glasspool et al., 
2000). However, due to cost reasons, low access and high false positives, MRI is not yet 
considered as a screening exam for breast cancer except for special cases. MRI of breast 
cancer is recommended in the repeated screening of patients who have the increased risk of 
radiation induced DNA mutations (Fass, 2008). MRI is used to screen women with a family 
history of breast cancer, women with very dense breast tissues or women with silicone 
implants that can obscure pathology in mammography (Fass, 2008).  
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2.4 Diffuse Optical Tomography (DOT) 
While breast cancer is still increasing in frequency, new diagnostic procedures must be 
available to challenge existing procedures to make diagnosis of breast cancer more accurate 
and reliable. DOT is one of the most important non-invasive and non-ionizing imaging 
modalities that are available for breast cancer diagnosis. DOT can be used to locate lesions 
within breast (Frangioni, 2008; Kepshire et al., 2007; Hawrysz et al, 2000). Despite promising 
results, there are several factors that limit the wide application of DOT for the imaging of 
breast tissue in clinic. First, the maximum depth of imaging in breast tissue is less than 15 
mm. Secondly, the spatial resolution of DOT is less than one centimeter, that is not as good 
as mammography, ultrasonography or MRI. Because of these limitations, DOT is not a 
widely-accepted imaging modality for breast cancer (Kepshire et al., 2007; Hawrysz et al., 
2000). 
2.5 Computed Tomography (CT) 
X-ray computed tomography (introduced into clinical practice in 1972) was the first of 
modern slice-imaging modalities. CT scan has several advantages including (1) unlimited 
depth penetration; (2) high spatial resolution; (3) short acquisition time (minutes); (4) 
moderately cheap and (5) ability of performing anatomical imaging. CT has some 
limitations including (1) sensitivity of CT scan decreases in early stage of breast cancer, (2) 
CT scan is associated with radiation exposure and should never be done in pregnant females 
because of radiation risk to the fetus, (3) CT is not very good at identifying pathology of soft 
tissues, (4) the dye used in CT is iodine based and is often a cause of allergy and (5) CT 
probably can not be used for molecular imaging and currently is just used for anatomical 
and functional imaging (Pysz et al., 2010).  
2.6 Measurement of tumor markers in blood 
Several biochemical compounds in the serum/plasma may act as the indicators of the 
presence, risk or prognosis of cancer. In patients with history of breast cancer, elevated 
tumor marker levels may represent cases of tumor relapse. It has been shown that increasing 
levels of tumor markers is associated with disease recurrence and may indicate the need for 
further investigations. Examples of tumor markers in blood including CA 15.3, CA 27.29, 
CA125, CEA and circulating tumor cells. While breast cancer blood marker tests are 
promising, they are not absolutely conclusive. When a breast cancer blood marker test 
comes back negative, it doesn't necessarily mean that the patient is free and clear of breast 
cancer and a positive result does not always mean that the cancer is growing (Merkle et al., 
2009).  
2.7 Nuclear medicine  
As cited, each imaging method has strengths and weaknesses in terms of sensitivity, 
specificity, spatial and temporal resolution, contrast and cost. Therefore, the fundamental 
efforts for introduction and development of new methods for breast cancer diagnosis are 
requested. Nuclear medicine is defined as a branch of medicine that employs open 
radioactive sources, commonly referred to radionuclides, in diagnosis and treatment of 
diseases (Glasspool & Evans, 2000). The application of nuclear medicine techniques to study 
patients with breast cancer has recently raised its profile particularly in the investigation of 
indeterminate mammographic lesions and for overcoming limitations of MRI, US, CT and 
www.intechopen.com
 
12 Chapters on Nuclear Medicine 168 
DOT techniques (Berghammer et al., 2001). The differences in tumor biology such as blood 
flow, metabolism, concentration of specific receptors or differences in antigen expression are 
exploited in order to target radionuclides to the tumor tissue (Glasspool & Evans, 2000). The 
major advantage of nuclear medicine is that just picomolar concentrations of radiotracers are 
required to provide a measurable signal (Cook et al., 2003). 
2.7.1 Scintimammography 
Future developments in nuclear medicine are in the area of development of specialized 
imaging systems. One example of specialized gamma camera is scintimammography in 
imaging of breast and axillary nodes. Scintimammography term is given to radionuclide 
imaging of breast cancer (Schillaci et al., 2007). Scintimammography is performed after 
injection of the radiopharmaceutical into an arm vein contralateral to the suspected tumor or 
into a pedal vein and the subsequent imaging with right and left lateral, prone and supine 
views, covering both breasts and both axillae and later computer acquisition of data 
(Nguyen et al., 2009; Brem et al., 2005). Most studies evaluating the role of 
scintimammography, have compared it with mammography, ultrasound and MRI. Its 
sensitivity has ranged from 62% to 93% with specificity from 79% to 94% (Schillaci & 
Buscombe, 2004). Its sensitivity is greater for palpable lesions. Current recommendations for 
the use of scintimammography are (Fass, 2008):  
1. As a general adjunct to mammography to differentiate between benign and malignant 
breast lesions in patients with palpable masses or suspicious mammograms. 
2. In patients referred for biopsy when lesions are considered to have a low probability of 
malignancy. 
3. In patients with probably benign findings on mammography, but are recommended for 
close follow-up (e.g. repeated mammography in 3–6 months).  
4. In patients who have dense breast tissues and are considered difficult to evaluate on 
mammography. 
5. For detection of axillary lymph node metastases in patients with confirmed breast cancer. 
The main limitations of scintimamography are low sensitivity and high dose of radionuclide 
that is used for imaging. Currently, for overcoming the cited limitations, the researchers are 
studying on targeted molecular imaging methods. 
3. Treatment of breast cancer  
To understand the diagnostic needs for breast cancer, it is important to understand the 
range of approaches for breast cancer treatment. With the exception of early and late stage 
disease, almost all breast cancer therapy methods, involve a combination of locoregional 
and systemic treatments. Locoregional therapy includes surgery and radiotherapy and 
systemic therapy includes chemotherapy, hormone therapy and targeted therapy. Because 
the breast cancer, that is metastatic beyond the regional node, is rarely cured, systemic 
therapy is the primary treatment for metastatic disease with locoregional treatment reserved 
for symptom control and is used possibly in some patients with limited metastatic disease 
who may achieve prolonged remissions. 
3.1 Surgery  
Surgery is the oldest and still the most widely used treatment modality that is available 
for breast cancer patients and can be accomplished by mastectomy, removal of the entire 
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breast or by breast-conserving surgery often termed lumpectomy of cancer. If the tumor is 
detected at early stage before spreading, surgery alone might be sufficient to reach 
complete remission. When the tumor is detected after spreading with distant metastases, 
surgery is frequently used in combination with radiotherapy or chemotherapy (Keshtgar 
et al, 2010). 
3.2 Radiotherapy 
In radiotherapy, also known as radiation therapy, high-energy ionizing radiation such as x 
or Ǆ-rays is irradiated to the tumor tissues for killing the cancer cells. Radiation can be 
delivered via external radiation from a source outside the body directing to the tumor or by 
an internal radiation source (brachytherapy) which is positioned inside the body adjacent to 
or inside the tumor. Radiation must affect only cancer cells in the treated area and not 
normal cells. To treat secondary tumors and stopping growth of any remaining tumor cells, 
radiation therapy is often used in conjunction with other treatment modalities like 
chemotherapy and surgery (Luini et al., 2007). 
3.3 Chemotherapy  
The use of cytotoxic chemotherapy, in both advanced and early stage of breast cancer, has 
made significant progress in the last decade (Hassan et al., 2010). Chemotherapy is a 
systemic breast cancer therapy and compared to surgery and radiation therapy, it has one 
advantage. It is able to eliminate cancer cells throughout the entire body. Chemotherapeutic 
agents currently approved for treatment of breast cancer are: anthracycline, alkaloids, 
topoisomerase inhibitors, alkylating agents, and antimetabolites. The important 
disadvantage of chemotherapy is side effects of drugs such as nausea, vomiting, fatigue, 
sore mouth, diarrhea, constipation and decreased blood cells count. These side effects can 
impact patient ability to tolerate treatment, maintain a healthy diet, stay active and enjoy a 
good quality of life (Hassan et al., 2010). 
3.4 Hormone therapy 
Hormone therapy, also called "endocrine-based therapy", is a systemic treatment and plays 
an important role in breast cancer therapy. It is the first type of systemic treatment directed 
at a specific target, the hormone-dependent cancer cell, and may be referred to "targeted 
therapy" (Hind et al., 2007). The purpose of hormone therapy is to add, block or remove 
hormones. There are certain hormones that can attach to breast cancer cells and affect their 
ability to multiply such as tamoxifen, fareston, arimidex and so on (Jones& Buzdar, 2004). 
Hormone therapy may be used alone or in combination with radiation therapy. It is rarely 
used simultaneously, but is often used following chemotherapy. The benefits and side 
effects of the drugs relate only to the natural effects of the hormone itself and the hormone-
cancer cell interaction. For that reason, the typical side effects seen with chemotherapy are 
not present with hormone or endocrine-based therapies (Hind et al., 2007). 
3.5 Immunotherapy 
Immunotherapy (also called biological therapy, biotherapy or biological response modifier 
therapy) of breast cancer uses patient body's natural ability (immune system) to fight the 
disease and/or to lesson treatment-related side effects (Diss et al., 1997b). The 
immunotherapy drugs are bound to specific proteins on breast cancer cells to slow or stop 
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their growth. Currently, there are at least three FDA-approved antibodies for targeting of 
breast cancers (Stipsanelli & Valsamaki, 2005; Disis et al., 1994a, 1997b): 
• Trastuzumab (Herceptin) that is bound to the extracellular domain of Her2/neu 
receptor 
• Pertuzumab that is bound to a different epitope of Her2/neu receptor 
• Bevacizumab that is bound to vascular endothelial growth factor receptors (VEGFRs). 
Immunotherapy of breast cancer may cause side effects such as fever, chill, pain, weakness, 
nausea, vomiting, diarrhea, headache, and rash. These side effects generally become less 
severe after the first treatment. In addition, immunotherapy is a very expensive method for 
patients. 
4. Targeted molecular imaging and therapy 
The researchers are trying to improve the methods that can decrease the dose of drugs and 
transfer them just to the tumor cells with high efficiency and kill the cancer cells without 
affecting healthy cells. The recent improvements in biology of tumor cells, have introduced 
new methods in diagnosis and therapy of cancer named targeted molecular imaging and 
therapy (Sawyers, 2004). The knowledge of the diversities between tumor and normal 
tissues is the key to identify novel targets for new selective diagnosis and therapeutic 
strategies (Gasparini et al., 2005). The aim of these methods is to deliver a drug for therapy 
or a contrast agent for imaging just to the tumor site or cancer cells using different 
technologies. In these methods, not only the dose of drugs is decreased, but also the damage 
to the normal tissues is decreased. On the other hand, the probability of the diagnosis and 
therapy is increased too. In addition, the targeting methods in comparison with other 
methods have fewer side effects and the patients tolerate less physical and mental hurts. 
Tumor markers are used for targeting cancer cells in molecular imaging and therapy 
methods. Tumor marker is objectively measured and evaluated as an indicator of normal 
biological processes, pathogenic processes or pharmacologic responses to a therapeutic 
intervention (Meel et al., 2010). 
4.1 Targeted molecular imaging  
Recent advances in molecular and cellular biology have facilitated the discovery of novel 
molecular targets on tumor cells such as key molecules involved in proliferation, 
differentiation, cell death and apoptosis, angiogenesis, invasion and metastasis or associated 
with cancer cell stemness (William et al., 2008). Molecular imaging is defined as 
visualization, characterization and measurement of biological processes at the molecular 
and cellular levels in human beings and other living systems (Pysz et al., 2010). Today, 
molecular imaging is increasingly used in clinical oncology, because molecular imaging is a 
non-invasive diagnostic method that allows for more sensitive and specific monitoring of 
key cancer-related molecular targets in vivo and is expected to play an important role in 
future cancer diagnosis. Generally, molecular targets can be applied to (Meel et al., 2010; 
Neves & Brindle, 2006):  
1. Detection: screening high-risk groups and large populations of asymptomatic 
individuals  
2. Diagnosis of cancer in individuals with signs or symptoms 
3. As a prognostic indicator 
4. Localization of tumor and metastases 
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5. Staging the extent of disease 
6. Monitor the clinical course of cancer patients 
7. Determine the effectiveness of therapy 
8. Early detection of recurrent or metastatic cancer 
A molecular imaging agent typically consists of a signaling moiety (radionuclide in nuclear 
medicine) and a functional target. Specific targeting of cancer-associated targets with 
radiolabeled targeting agents (e.g. antibodies, peptides and non-immunoglobulin proteins) 
and the use of subsequent visualization systems like gamma camera, SPECT and PET are 
examples of molecular imaging methods in nuclear medicine. 
4.2 Targeted molecular therapy 
Major advances in molecular biology, cellular biology and genomics have substantially 
improved our understanding of cancers. Now, these advances are being translated into 
therapy. The term targeted therapy ideally connotes the ability to identify a known 
therapeutic target that is important in the biology of cancer cells and use a specific agent that 
can treat the disease by modifying the expression or activity of the target in the growth and 
progression of the cancer. With this approach, only patients with a likelihood of benefit are 
treated, so the therapeutic index will hopefully be improved. Selecting a biologically active 
target is usually the first step in molecular imaging research and leads to the design of a 
molecular imaging agent. Potential targets include proteins, DNA, RNA, carbohydrates and 
lipids. Several properties of these biomolecules as imaging targets need to be considered 
that are summarized in the following (Meel et al., 2010):  
1. High specificity (i.e. binding specifically to a tumor-associated molecular target with 
minimal non-specific binding to non-target molecules).  
2. High target binding affinity (low subnanomolar binding is typically desired).  
3. Small size (enabling fast distribution to the tumor and quick clearance from the blood 
and other compartments).  
4. High structural stability for labeling with signaling agents. 
5. Available ligands that specifically target these biomolecules. 
5. Targeted molecular agents of breast cancer 
Molecular probes in nuclear medicine are the proof of principle for targeted molecular 
imaging and therapy. Molecular nuclear medicine holds the unique potential of being able 
to find, diagnose and treat diseases as well as to monitor treatment response. Several 
molecular targeting agents have been approved for clinical uses in nuclear medicine. Many 
others are under preclinical evaluation with high potential for clinical applications. The 
molecular targeting agents, that are common in nuclear medicine, are small molecules, 
oligonucleotides /PNAs, affibodys, peptides and antibodies.  
5.1 Small molecules 
Several radiolabeled small molecules have been applied for the detection and therapy of 
breast and prostate tumors and leukemia (Cornelissen & Vallis, 2010). For example, 
radiolabeled estrogens and estrogen receptor antagonists are bound to the estrogen receptor, 
a nuclear membrane receptor, which then translocate to the nucleus. 123I- tamoxifen, an 
estrogen receptor (ER) antagonist, has been used as a diagnostic tool to determine estrogen 
receptor status in patients with breast or head-and-neck cancer (Wiele et al., 2001). Other 
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small-molecule radiopharmaceuticals include 125I-daunorubicin, 111In-folate, 123/131I 
metaiodo- benzyl-guanidine (MIBG), 125I-iododeoxyuridine and 111In-bleomycin (Jalilian 
et al., 2006, 2007). Small molecules such as tyrosine kinase inhibitors (TKIs) are less specific 
than therapeutic monoclonal antibodies (mAbs) (Huang & Armstrong,2004) and some of 
them can inhibit multiple targets simultaneously including cell receptors or signal 
transduction pathway proteins leading to a higher risk for toxicity (Xia et al., 2005). 
5.2 Oligonucleotides/ PNAs/ MORF 
The natural ability of oligonucleotides and the oligonucleotide mimetic peptide nucleic 
acids (PNAs) and phosphorodiamidate morpholinos (MORF) to anneal with RNA and DNA 
makes them the appealing vehicles to bring radionuclides in close proximity to the 
RNA/DNA. Both 125I and 111In have been used to radiolabel oligonucleotides and have 
been applied successfully to target over-expression of certain genes involved with cancer 
(Cornelissen & Vallis, 2010).  
Aptamers are synthetically based DNA or RNA oligonucleotides that are highly stable 
structures and are considered to have low immunogenicity. They are selected for their 
ability to bind to a target of interest (Perkins & Missailidis, 2007). Hicke et al. demonstrated 
that the aptamers cleared quickly from the blood, reaching maximum tumor uptake within 
10 min, but then decreasing to approximately 2% by 3 h. However, the rapid clearance from 
the blood and tissues resulted in highly favorable tumor/blood and kidney ratios but there 
was considerable additional clearance of the 99mTc through the liver and intestines (Hicke 
et al., 2006). However, using aptamers as the radiopharmaceuticals needs further 
improvements. 
5.3 Affibody molecules 
Affibody molecules are 58 amino-acid, three-helix bundle affinity proteins and are derived 
from the β-domain of the five-domain Ig-binding region protein A from Staphylococcus 
aureus (Orlova et al., 2007). They represent highly specific binders, selected by phage display 
from a library generated by randomization of 13 amino acids in helix 1 and 2, which are 
responsible for the Fc-binding site. Recently, affibody molecules have been investigated for 
tumor targeting purposes both for targeted imaging and therapy. The first generated and 
used affibody molecule for radionuclide imaging was ZHER2 with a binding affinity of 50 nM 
to HER2 protein (Capalaet al., 2009). Affibody molecules represent a promising novel class 
of targeting molecules that can be used as relatively small, high-affinity, cancer-specific 
ligands and that are well suited for tumor molecular imaging and therapy, providing a 
possible new route for imaging of tumor-specific receptors (Orlova et al., 2006). Since these 
structures are derived from a Staphylococcal protein, the potential immunogenicity of these 
molecules may be a concern (Sharkey & Goldenberg, 2008). 
5.4 Peptides 
During the past decade, proof of the principle that peptide receptors can be used 
successfully for in vivo targeting of human cancers, has been provided (Ferro-Flores et al., 
2010). Peptides used for tumor targeting show some advantages over antibodies. Peptides 
are small and show rapid diffusion into the target tissues resulting in rapid 
pharmacokinetics (Ferro-Flores et al., 2010). Their fast blood clearance can lead to high 
tumor to background ratio shortly after administration of the radiopeptide. In addition, they 
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can tolerate harsh chemical conditions and are easy to be purified and modified. The 
common peptides that are used in molecular imaging and therapy of breast cancer are 
somatostatin, bombesin, neuropeptide Y (NPY) and vasoactive intestinal peptide (VIP) 
(Ferro-Flores et al., 2010). The important disadvantage of peptides is rapid degrading from 
blood by endogenous peptidases and proteases (Ferro-Flores et al., 2010). 
5.5 Antibodies 
Antibodies are now increasingly recognized as important biological agents for the detection 
and treatment of cancer (Sharkey & Goldenberg, 2006). In the 1970s, polyclonal antibodies 
were already essential components of medical diagnosis as well as for therapy as antitoxins 
for the prevention of tetanus and other diseases (Goldsmith & Signore, 2010). The 
development of monoclonal antibody technology by Kohler and Milstein in the 1970s 
accelerated the exploitation of the chemo-specificity of antibodies for diagnostic and 
therapeutic purposes (Goldsmith & Signore, 2010). In the last two decades several different 
monoclonal antibodies have been approved by the Food and Drug Administration (FDA) for 
therapeutic purposes and some of these have also been radiolabeled for diagnostic and 
therapeutic purposes (Xiao et al., 2008). For imaging, it is highly desirable that targeting 
agents are rapidly excreted from the body. It is also essential that the targeting agent binds 
rapidly to its target, reducing the time between injection and imaging. The application of 
monoclonal antibodies for therapy and diagnosis is limited by generation of an immune 
response known as human anti-mouse antibody (HAMA) response (Salouti et al., 2011). One 
of the most successful approaches to overcome immunogenicity is ”humanization” of rodent 
mAbs by genetic engineering (Waldmann&Morris, 2008). A simple approach to make an 
antibody to be more humanized is the replacement of the constant domains of the antibody 
with constant domains of a human antibody. The resulting chimeric antibody contains only 
the variable regions of murine origin and would therefore be expected to be less 
immunogenic in people. Many chimeric antibodies have been prepared and shown to retain 
the full antigen binding ability of the parent murine antibody as well as taking on the 
constant region effecter functions of the human antibody used (Waldmann&Morris, 2008). 
Humanization of rodent antibodies can be taken further to produce fully humanized 
antibodies in the form of reshaped, engineered human antibodies, in which much of the 
variable domain sequences are also replaced by human antibody sequence. In these 
approaches, the antigen binding loops are derived from the rodent antibody and much of the 
supporting framework is humanized (Waldmann&Morris, 2008). Targeting agents that have 
been approved for breast cancer include trastuzumab and pertuzumab directed against 
human epidermal growth factor receptor 2 (HER2) and bevacizumab, directed against 
vascular endothelial growth factor (VEGF) (Goldsmith & Signore, 2010). Several other 
targeting agents are currently under evaluation in preclinical and clinical trials (Carl & 
Roland, 2001). 
5.5.1 Antibody derivatives 
The use of mAbs has presented challenges in radionuclide imaging. Because of their large 
size (molecular weight of ~150 kDa), mAbs penetrate slowly and have long residence time 
in the blood circulation (days-weeks) due to active recycling by the neonatal Fc receptor, 
leading to limited tumor-to-normal organs ratio in biodistribution and low contrast images 
for the detection of biomarkers/tumors (Jonathan et al., 2000). Advances in protein 
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engineering have led to a number of alternative constructs for imaging and therapy. These 
alternatives characterized by smaller size include: 
• Fragment antigen binding (Fab): The area around the antibody hinge is more 
susceptible to proteolysis than the tightly folded domains and thus this is the point at 
which cleavage usually takes place. Proteolysis above the disulphide bonds in the hinge 
region with, for example papain, results in Fab fragments which are monovalent for 
antigen binding (~55 kDa). 
• Divalent fragment antigen binding (F(ab´)2): If antibody proteolysis occurs below the 
hinge disulphide bonds, with enzymes such as pepsin, it results in a divalent F(ab´)2 
fragment (~110 kDa). 
• Single chain fragment (scFv): This antibody fragment consists only the variable heavy 
(VH) and the variable light (VL) chain of an antibody tethered together by a flexible 
linker, attaching the carboxyl terminus of the VL sequence to the amino terminus of the 
VH sequence (~25 kDa). 
• Nanobody: Nanobodies are small antibody fragments (15 kDa) derived from the 
naturally occurring heavy-chain-only antibodies (Friedman. et al., 2009). These 
fragments have also been referred to VHH as they consist of a variable domain (VH) of 
the heavy chain (H) of antibodies (Meel et al., 2010). 
When compared to intact IgGs, these antibody fragments have the advantages of faster 
biodistribution, rapid penetration into the tissues and improved tumor-to-normal organs 
ratio. These forms (e.g. F(ab')2, Fab or other molecular constructs) achieve maximum tumor 
accretion more quickly with improved tumor/blood ratio that make earlier visualization, 
possible (Colcher et al., 1998). The use of fragments of antibodies has also been advocated as 
a possible means to reduce the immunogenicity of rodent antibodies in human beings. 
Antibody fragments generated by proteolysis or by genetic engineering, have been tested 
both in vitro and in vivo. As monovalent binding entities, antibody fragments suffer from 
relatively low avidity binding. Hence, to increase their binding avidity, they have also been 
engineered into multivalent constructs include: 
• Diabody: ”Diabody” is one of the engineered multivalent constructs. Diabodies can be 
produced to high levels in the form of stable dimmers (Wu & Yazaki, 2000; Hudson & 
Kortt, 1999; Lawrence et al., 1998). However, the stability of such dimeric species varies 
from one antibody to another. 
• Tribody: In some cases, particularly with direct fusions of VH and VL, stable trimeric 
species are produced which have been termed ”tribody” (Todorovskaet al., 2001). Some 
tribodies show improved avidity for antigens as expected from the increased number of 
binding sites, although this is not always the case (Todorovskaet al., 2001).  
6. Target antigens 
In recent years, there has been a significant improvement in the understanding of molecular 
events and critical pathways involved in breast cancer. The studies have confirmed the 
feasibility of using radiolabeled antibodies for imaging and therapy of primary and 
metastatic breast cancer and that a diverse array of molecules can serve as targets for 
localizing antibodies (Carlos et al., 2006). Theoretically, an ideal target for radionuclide 
detection and therapy of metastatic breast cancer would be tumor-specific, generously 
expressed on all the breast cancer cells, not expressed by normal tissues and not released 
into the blood circulation (Mohammadnejad et al., 2010). For antibody screening of breast 
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cancer, it is essential that the antibody is well characterized with little cross-reactivity to 
other antigens. The antibodies show cross-reactivity with, e.g. leucocytes, potentially 
yielding false-positive images. The majority of breast cancer targeting antibody studies have 
used antibodies against MUC1, CEA, TAG-72 and L6 antigens (Carlos et al., 2006).  
6.1 CEA  
First described by Gold and Freedman in 1965, CEA was thought to be a specific marker for 
colon adenocarcinoma. However, subsequent studies demonstrated CEA expression in 
other human adenocarcinomas including the surface membrane of breast cancer cells 
(Jonathan et al., 2000). Expression of CEA has been reported in 10% to 95% of breast cancers 
(Hong et al., 2008, Denardo, 2005). Preliminary studies with 99mTc-labeled CEA antibody 
appeared to indicate a useful role for this agent in distinguishing between benign and 
malignant breast lesions in patients with indeterminate mammographic findings (Denardo, 
2005). Therapy studies specifically in breast cancer have also been performed with T84.66 
(Koppe et al., 2005). T84.66 is a well characterized murine IgG1 antibody with high 
specificity and affinity for a unique epitope of CEA molecules. A chimeric form of T84.66 
(cT84.66) has been also used in clinical studies for the scintigraphic detection of breast 
cancer and in phase I/II therapy trials and scFv-based anti-CEA constructs are under study 
(Denardo, 2005). Another mAb that has been classified in this group is NP4. NP-4 belongs to 
the murine IgG1 subclass and is specific for CEA, reacting with a class III peptide epitope of 
CEA molecules (Richman & DeNardo, 2001). 
6.2 MUC-1  
MUC-1 mucins are large, complex glycoproteins that have a polypeptide core with multiple 
oligosaccharide side chains (Mukhopadhyay et al., 2011). The mature molecule is anchored 
within the cell surface by a characteristic transmembrane domain, but most of the mucins 
are expressed extracellular. This polar distribution is lost with neoplastic transformation and 
increased heterogenous MUC-1 synthesis is a common feature of breast cancer. This 
glycoprotein is aberrantly over expressed in adenocarcinomas including 80% of breast 
cancers (Salouti et al., 2011). Targeting, using antibodies directed against the MUC-1 antigen 
has been tested in patients with breast cancer using various antibodies. BrE-3 is an IgG1 
antibody directed against the peptide epitope of the MUC-1 antigen that have been 
evaluated for RIT (Mohammadnejad et al, 2010). The studies of the application of BrE-3 
mAbs in patients with breast cancer showed minimal cross reactivity with normal breast 
tissues (Howell et al., 1995; Blank et al., 1992). Because the majority of the patients rapidly 
showed HAMA response against the murine BrE-3 mAb, a humanized version of BrE-3 
(hBrE-3) was developed (Kramer et al., 1993). Kramer and colleagues investigated the 
pharmacokinetics and biodistribution of 111In-MX-DTPA-labeled hBrE-3 in seven patients 
with metastatic breast cancer (Kramer et al., 1993). hBrE-3 was proved to have a lower 
immunogenicity compared to murine BrE-3 (only one patient developed a HAMA response) 
while tumor-targeting properties were preserved (Denardo, 2005). Monoclonal antibody 
170H.82 (m170) is a murine IgG1 prepared using a synthetic asialo GM1 terminal 
disaccharide immunogen related to the Thomsen–Friedenreich disaccharide and selected by 
reactivity with MUC-1 expressing cancer cell membranes (Jonathan et al., 2000). The results 
of experimens showed that labeled m170 was effective for imaging of primary and 
metastatic breast cancer and was able to detect lesions as small as 1 cm in size using SPECT 
with an overall clinical accuracy of 92%. In particular, mAb 170H.82 has been studied in 
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breast cancer patients, with reported a sensitivity and specificity for detecting locoregional 
soft tissue disease of 90% and 93%, respectively (Denardo, 2005). Because aberrant MUC-1 
has provided effective target for breast cancer, gene-engineered antibody fragments (scFv) 
have been developed to MUC-1 antigen by phage display immunoglobulin gene libraries 
from mice immunized with MUC-1 peptide core and MCF-7 membranes. Numerous other 
monoclonal antibodies have been generated against MUC1 and have been used for breast 
cancer imaging such as HMFG-1 and HMFG-2, SM3, DF3, 12H12, BM2 (formerly called 2El 
1), BM7, EBA-1, MA5 and PR81 (Richman & Denardo, 2001; Salouti et al., 2008). Although, 
not all of these antibodies necessarily react with the same MUC1 determinant, they have all 
shown the ability to target breast cancer either in animal xenografts or in patients. Thus, 
these antibodies have been shown to be suitable antibodies for radioimmunoscintigraphy 
and radioimmunotherapy studies in this cancer type.  
6.3 TAG-72  
Immunohistochemical and immunocytochemical techniques have demonstrated preferential 
expression of TAG-72 known as tumor-associated glycoprotein in breast, gastrointestinal 
and ovarian adenocarcinomas compared to normal tissues (Denardo, 2005). Antibodies 
against the TAG-72 antigen particularly B72.3 and chB72.3 were evaluated in patients after 
careful study in human xenograft mouse models (Lorraine et al., 1998). The TAG-72 target 
antigen reactive with B72.3 pancarcinoma antibody has been used to target and image breast 
cancer (Denardo, 2005). CC49, a newer antibody to a different epitope of TAG-72, is a 
murine IgG1 monoclonal antibody that was labeled with Lutitium-177 by Milenic et al. 
(Milenic et al., 1991). He found that Lutitium-177 was an attractive alternative radionuclide 
with a lower energy beta emission and longer half life than 90Y. The images demonstrated 
the activity uptake at the site of tumor as well as in bone marrow. 
6.4 L6  
L6 cell surface antigen is a 24-kDa surface protein containing 3 hydrophobic transmembrane 
regions that are followed by a hydrophilic region (Richman & Denardo, 2001). L6 antigen is 
related to a number of cell surface proteins with similar predicted membrane topology that 
have been implicated in cell growth. L6 antigen is highly expressed in 50% of breast cancer 
specimens. Two mAb of this family, L6 mAb and the chimeric version (ChL6) have been 
studied in clinical trials (Denardo et al., 1994). 131I-Chimeric L6 antibody demonstrated 
therapeutic promise for patients with breast cancer (John et al., 2009). 
6.5 EGFR  
Epidermal growth factor receptor (EGFR) is a family of transmembrane growth factor 
receptor tyrosine kinases involved in regulation of cell proliferation and survival of 
epithelial cells (Cleator & Heller, 2007). EGFR family includes four receptors: EGFR/ErbB1, 
HER2/ErbB2, HER3/ErbB3 and HER4/ErbB4. EGFR and HER2 are over expressed in 
approximately 40% and 25% of breast cancers, respectively and associated with aggressive 
clinical behavior and poor prognosis. Due to the important roles of EGFR and HER2 
receptors in diagnosis and therapy of breast cancer patients, both receptors are discussed in 
details (Munagalaet al., 2011). 
• EGFR receptor  
EGFR (also known as ErbB1 or HER1) is a 170 kDa transmembrane protein with an 
intracellular tyrosine-kinase domain. Many epithelial cancers including tumors of the head 
www.intechopen.com
 
Breast Cancer: Radioimmunoscintigraphy and Radioimmunotherapy 177 
and neck, breast, colon, lung, kidney, prostate, brain, bladder and pancreas overexpress 
EGFR. Such overexpression is associated with poor prognosis and this leads to several 
strategies to block this pathway and improve the outcome. Cetuximab is a chimeric IgG1 
monoclonal antibody that competes with an endogenous ligand to bind to the extracellular 
domain of EGFR (Harris, 2004). On the basis of these findings and those of previous studies, 
Cetuximab received FDA approval in February 2004, for using in treatment of EGFR-
positive metastatic colorectal cancer (Harris, 2004). 
• HER2/Neu receptor 
The HER2/Neu receptor is a member of the EGFR family and another important cancer-
related receptor that is over expressed in several human tumors notably on a subset of 
breast cancer cells (Ross et al., 2004). Trastuzumab (commonly referred to Herceptin) was 
the first recombinant bivalent humanized mAb targeted against extracellular domain of 
HER2 reported in 1998, has been approved by FDA and is frequently used clinically in 
“naked antibody” therapy (Rasaneh et al., 2009). Trastuzumab binds with high affinity to 
HER2 and leads to internalisation of HER2 receptor and blockage of signal transduction. 
Unlike chemotherapy, trastuzumab do not have toxic effects such as nausea, vomiting, hair 
loss and bone marrow toxicity (Munagala, 2011). Pertuzumab, a recombinant humanized 
monoclonal antibody, binds to extracellular domain II of HER2 receptor and blocks its 
ability to dimerize with other HER family receptors (HER1, HER2, HER3, HER4) (Untch, 
2010). Pertuzumab is the first in a new class of targeted agents known as HER dimerization 
inhibitors (HDIs). The drug showed promising activity with trastuzumab in the treatment of 
metastatic breast cancer in a phase II study (Baselga et al., 2007, 2010). The patients treated 
with trastuzumab have an increased risk of developing cardiac dysfunction (Widakowich et 
al., 2007). When trastuzumab was conjugated with a radioneclide, the dose of drug was 
decreased that led to decrease its cardiac toxicity (Harris, 2004). Radioactive anti-HER2/neu 
rhumAb are considered attractive agents for RIS and RIT of aggressive HER-2/neu-positive 
breast carcinomas (Munnink, 2009). 
6.6 VEGF  
Vascular-endothelial growth factor (VEGF) is a proangiogenic growth factor that regulates 
vascular proliferation and permeability and is an antiapoptotic factor for new blood vessels. 
VEGF acts via two receptors, VEGFR1 and VEGFR2, which are expressed on the vascular 
endothelium. VEGFR expression is commonly increased in response to hypoxia, oncogenes 
and cytokines and its expression is associated with poor prognosis. Bevacizumab (Avastin) 
is a humanised monoclonal antibody that inhibits angiogenic signaling. In February, 2004, 
bevacizumab received FDA approval for using in the first line treatment of metastatic 
colorectal cancer in combination with 5-fluorouracil-based chemotherapy (Munnink, 2009). 
FDA is still moving toward stripping the cancer drug bevacizumab of its indication for 
treating advanced breast cancer, but not other cancers (Munnink, 2009). 
7. Radioimmunoscintigraphy 
It is well known that mammography provides a high sensitivity at the cost of relatively low 
specificity. Therefore, breast cancer diagnosis requires an adjunctive test to mammography 
that can increase diagnostic specificity while maintaining a high positive predictive value. 
Although sestamibi imaging has been introduced as an adjunctive test to mammography, it 
fails to provide the necessary sensitivity, specificity and predictive values for nonpalpable 
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lesions, thus resulting in a relatively high false-positive rate in patient population. Several 
strategies have been developed over the past two decades for earlier and more accurate 
diagnosis of disease and to evaluate response to therapy. One of the novel approaches for 
specific detection of cancers is the use of monoclonal antibodies conjugated with 
radionuclides so-called radioimmunoscintigraphy (is also called radioimmunodetection, 
radioimmunoimaging and radioimmunodiagnosis) (Salouti, et al., 2006). In this method, a 
radio-isotope labeled antibody is administered to a patient with cancer. Once localized to the 
tumor tissue, the radioisotope (and hence the sites of malignancy) can be detected with a 
nuclear medicine imaging system like gamma camera. The summery of history for RIS has 
been shown in table 1. The efficacy of this technique depends on antigen expression on tumor 
cells compared to normal tissues. Affinity, specificity, pharmacokinethics, properties of the 
radionuclide and imaging technique have influence on the efficacy of 
radioimmunoscintigraphy. The potential clinical applications of RIS are (1) evaluation of 
patients with suspected breast cancer, (2) locoregional staging of newly discovered breast 
cancer, (3) detection of distant metastases using whole body scintigraphy and (4) evaluation of 
tumor response to therapy (Berghammer et al., 2001).  
 
1908 
Paul Ehrlich is generally recognised as the inventor of the term “magic bullets”, 
describing the potential of an antibody to specifically target tumor cells. 
Ehrlich, 1906 
1953 
This approach was invented by Pressman and his associates who discovered that 
radioiodinated antisera could concentrate selectively in tumors when injected 





Gamma camera as initially introduced in 1957 by Hal Anger was designed to 
detect gamma photons within an energy window between 30 and 300 keV. 
Anger et al., 
1957 
1963 
David Kuhl and Roy Edwards were the first to present tomographic images using 
the Anger camera by acquiring multiple planar images from different angles and 





Gold and Freedman discovered carcinoembryonic antigen (CEA), the first well 
defined tumor-associated antigen and as a result of this finding purified 






Discovery of the hybridoma technique by Kohler and Milstein was perhaps the 
single most important contribution to the development of 
radioimmunoscintigraphy. Using the hybridoma technique, mass production 









Methodologic improvements included the combined use of optimized 
radionuclide tracers such as SPECT and antibody fragments such as Fab 
fragments to improve the quality of nuclear medicine images of metastatic cancer 
in vivo. 
Larson et al., 
1983a, b 
1986 
As a further advancement of chimeric mAbs, in 1986, Jones et al.  reported the 
production of humanized monoclonal antibodies. 
Jones PT et 
al.1986 
1998 
Trastuzumab (Herceptin) was approved by  FDA for using in patients with 
metastatic breast cancer. 
Cobleigh et al, 
1999 
2004 
Radioactive anti-HER-2/neu rhuMAb were considered attractive agents for 
radioimmunodiagnosis of aggressive HER-2/neu-positive breast carcinomas. 
Olafsen et al, 
2004 
Table 1. The summery of history for radioimmunoscintigraphy. 
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7.1 Radionuclides for imaging 
The most common radionuclides in nuclear medicine are 99mTc, 123I, 67Ga and 111In. Lower 
energy Ǆ-rays are readily absorbed in tissues and therefore less useful for external imaging. On 
the other hand, highest energy Ǆ-rays cause to decrease the sensitivity of imaging system 
(Berghammeret al., 2001). Technetium-99m is so far the most commonly used radionuclide in 
nuclear medicine (Hamoudeh et al., 2008). This is due to the highly interesting physical 
properties of 99mTc which is advantageous for both effective imaging and patient safety 
perspectives. Its properties include short half-life (6 h), gamma energy at 140 keV with 
practically no alpha or beta emissions and latent chemical properties, facilitating thereby the 
labeling of several types of kits for versatile diagnostic applications and readily available and 
inexpensive (it is derived as a column elute from a 99Mo/99mTc generator) (Verhaar et al., 
2000). It is most often used with smaller antibody forms such as Fab, scFv, diabodies and 
nanobodies. The gamma-ray emitting radionuclides are commonly used in gamma camera 
and single photon emission tomography (SPECT). Other groups of diagnostically used 
radionuclides are ß+ emitters such as 11C, 18F, 13N and 15O (Hamoudeh et al., 2008). The 
positron emitting radionuclides are used in positron emission tomography (PET). The positive 
electron travels only a short distance through the tissues and interacts with a free or loosely 
bound negative electron. The outcome of this interaction is two photons, consisting each of 511 
keV energy and being given off in opposite directions (Boswell & Brechbiel, 2007). 
7.2 Imaging systems in nuclear medicine 
Imaging systems in nclear medicine include gamma camera, single photon emission 
computed tomography (SPECT) and positron emission tomography (PET). 
7.2.1 Gamma camera  
Gamma camera is a one-headed, variable-angle diagnostic instrument that is used to image 
gamma radiation emitting radioisotopes, a technique known as scintigraphy. Gamma 
camera consists of a scintillation crystal, optically coupled to an array of photomultiplier 
tubes which converts the Ǆ-rays into electric signals.  
7.2.2 Single photon emission tomography 
Single photon emission computed tomography (SPECT) is a sensitive nuclear imaging 
technique that provides a 3D spatial distribution of single-photon emitting radionuclide within 
the body (Gomes et al., 2010). Multiple 2D images, also called projections, are acquired from 
multiple angles around the patient and subsequently reconstructed using the reconstruction 
imaging methods to generate cross-sectional images of the internal distribution of the injected 
molecules (Wernick, & Aarsvold,2004). Because of the isotropic emission of Ǆ-rays, a geometric 
collimation is needed to restrict the travelling direction of the emitted Ǆ-rays from the body, 
through the use of lead collimators. In clinical systems, collimators typically have many 
parallel holes that produce no magnification. The photons that travel in other directions than 
those specified by the aperture of collimator are absorbed and do not contribute to the image, 
which reduces the detection efficiency and sensitivity of SPECT as compared to PET (Madsen, 
2007).  SPECT have several advantages including (1) whole body imaging, (2) quantitative 
molecular imaging and (3) can be combined with CT for preparing anatomical information. 
The disadvantages of this method are radiation exposure, low spatial resoulation (0.3-1 mm, 
12-15 mm3) and long acquisition time (Pysz et al., 2010). 
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7.2.3 Positron emission tomography (PET) 
Positron emission tomography is a nuclear medicine technique that produces high 
resolution tomographic imaging through the detection of high energy photon pairs emitted 
during positron decay (Costelloeet al., 2009). This method was initially developed in 1960s, 
but has largely been used as a research tool. However, PET can provide useful information 
for clinical practice. The images generated by PET represent the metabolic activity of the 
underlying tissues and can therefore distinguish benign from malignant lesions on the basis 
of differences in metabolic activity. Similarly, it can identify recurrent diseases in areas in 
which conventional scans are difficult to interpret because of prior treatment (Costelloeet al., 
2009). PET represents the most advanced imaging technique, because it not only allows a 
three-dimensional image reconstruction, but also it can quantify the activity uptake (Fass, 
2008). It combines the highest degree of sensitivity with a resolution of currently, 5-7 mm. 
The principal applied radionuclide for PET is Fluor-18 (18F) which is known for its ideal 
half-life to manage (1.83 h). The development of radiopharmaceutical [2-18F]-2-fluoro-2-
deoxyglucose (18FDG) has been so far an important progress for PET imaging in oncology 
(Berghammer et al., 2001). 18FDG acts as a glucose analogue allowing for the visualization 
of glucose consumption, a metabolic process being massively enhanced in many 
malignancies (Einat & Moshe, 2010). PET has several advantages include (1) unlimited 
depth penetration; (2) whole body imaging possible, (4) quantitative molecular imaging and 
(5) can be combined with CT or MRI for anatomical information (Pysz et al., 2010). The 
disadvantage of PET is that it requires a conveniently located and expensive cyclotron and 
radiochemistry facilities to produce the short-half life isotopes and to incorporate these into 
suitable probe molecules (Fass, 2008).  
8. Radioimmunotherapy 
The first theory on the existence of proteins with specific binding capabilities to pathogenic 
organisms, thus acting as "magic bullet"’, was postulated at the end of the 19th century by the 
german pathologist Paul Ehrlich (Enelich, 1906). He was the first to recognise antibodies for 
their ability to differentiate between normal cells and transformed malignant cells. He 
specifically introduced immunotherapy as a potential treatment modality for targeting and 
treating tumors. After it had been recognized in 1950 that proteins could be labeled with 131I 
without significantly altering their immunological specificity (Eisen & Keston, 1950), Pressman 
and Korngold tested the tumor-targeting potential of a 131I-labeled rabbit antiserum in rats 
bearing osteosarcoma and confirmed preferential antibody uptake in the tumor xenografts 
(Pressman & Korngold, 1953). The first clinical trial investigated the therapeutic efficacy of 
radiolabeled antibodies was performed in the 1950s by Beierwaltes, who treated fourteen 
patients with metastatic melanoma with 131I-labeled rabbit antibodies and reported a 
pathologically confirmed remission in one patient (Beierwaltes, 1974). In 1965, Gold and 
Freedman discovered carcinoembryonic antigen (CEA), the first well defined tumor-associated 
antigen. The purified polyclonal anti-CEA antibodies were shown to localize to CEA 
expressing tumors in vivo (Gold & Freedman, 1965). In the late 1970s, Goldenberg and 
colleagues successfully targeted colon cancer in patients using a polyclonal goat anti-CEA 
antiserum (Goldenberg et al., 1978). Nowadays, CEA has not only become one of the most 
extensively used tumor markers in clinical oncology, but also due to its pronounced 
expression in various carcinomas, it is one of the most targeted antigens in RIT. In 1975, Köhler 
and Milstein reformed the field of radioimmunotargeting as they introduced the hybridoma  
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technology, a method that made it possible to produce large quantities of monoclonal 
antibodies with high purity and reproducibility (Kohler & Milstein, 1975). Since then, 
numerous antigen-antibody systems have been established and several of the antibodies have 
been taken to clinical trials. Radioimmunotherapy is a method of selectively delivering 
radionuclides with toxic emissions to cancer cells, while reducing the dose to normal tissues. 
Using mAbs labeled with radionuclides has two major advantages over the application of 
mAbs conjugated with either drugs or toxins. Firstly, tumor cells not expressing the target 
antigen can still be sterilized by the so-called crossfire phenomenon, i.e., radiation energy 
emitted by radionuclides bound to antibodies targeting adjacent tumor cells. Secondly, 
radionuclides are not subject to multidrug resistance. Although promising, RIT has been less 
effective for solid tumors, in part because they are less radiosensitive. However, early 
micrometatasis of breast cancer have been demonstrated to be radiosensitive (Koppe et al., 
2005). On the other hand, an advantage of RIT is that it can target small metastatic lesions that 
are undetected by conventional scanning and would otherwise remain untreated. In addition, 
RIT is able to target multiple metastases throughout the body in a single treatment. 
8.1 Radionuclides for treatment 
The selection of a radionuclide for cancer treatments depends on several parameters including:  
1. Physical parameters: The type of radiation emitted by the radionuclide, required 
energy necessary for therapy and half-life of the radionuclide are physical parameters 
that must be considered. The type of radiation and the content of its energy are 
important factors that determine what radionuclide is suitable for killing of single 
disseminated cells, small metastases or large cancer tissues. The physical half-life of the 
radionuclides should preferably be in the same order of magnitude as the biological 
half-life. A too long physical half-life increases the necessary amount of radionuclide to 
be delivered to the tumor cells to allow the reasonable amounts of decays before 
excretion. A shorter physical half-life, on the other hand, will not give enough time for 
the targeting process to take place. It seems reasonable to assume that the most suitable 
physical half-lives ranges from a few hours up to some days when targeting of 
disseminated cells is considered (Boswell & Brechbiel, 2007). 
2. Chemical parameters: The chemical parameters are as follow: achievable specific 
activity, stability of the radionuclide/antibody complex after labeling and that the 
labeling procedure must not interfere with the immunological activity of the antibody. 
3. Biological parameters: tumor type, size and location, antibody kinetics, antigen density 
and heterogeneity and antigenicity are the most important biological parameters.  
4. Other parameters: radioisotope availability and its cost. 
Three main categories of radionuclides have been investigated for their potential therapeutic 
characterisation in radioimmunotherapy including ǃ-particle emitters, ǂ-particle emitters 
and auger electron cascades. 
1. ┚-particle emitters 
So far, the vast majority of preclinical and clinical studies have been made to use ǃ-emitting 
radionuclides such as 131I, 90Y, 186Re and 188Re. These radionuclides have a tissue range of 
about several millimeters. This can create a ‘‘cross fire’’ effect, so that antigen or receptor 
negative cells in a tumor can also be treated. High energy B-particles are not efficient for 
killing of single disseminated cells or small metastases. So, ǃ-particle therapy is preferred for 
large tumors (Boswell & Brechbiel, 2007). 
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2. ┙-particle emitters  
Radionuclides emitting ǂ-particles such as 225Ac (half-life 10 days), 211At (half-life 7.2 h), 
212Bi (half-life 60.55 min) and 213Bi (half-life 45.6 min) are options for treatment of small 
tumor nests or single disseminated tumor cells. Alfa particle emitting radionuclides are 
short ranged, high-energy helium nuclei with a high linear energy transfer (LET). As a 
consequence, ǂ-emitters have a high relative biological effectiveness (RBE) which means, if 
nuclear localisation is possible, fewer radionuclides per cell are needed (Fass, 2009).  
3. Auger electron cascades 
Auger-electrons, discovered by Lise Meitner in 1922 and by Pierre Auger in 1923, are 
formed when the vacancy created in an inner shell is filled with an electron from a higher 
energy level after electron capture. Auger-electrons have high LET Like ǂ-particles 
(Cornelissen & Vallis,  2010). Auger-electron emitters, like 125I, deposit a concentrated 
amount of energy in even shorter distances than ǂ-emitters. This means that these 
radionuclides need to be located in the vicinity of the tumor cell nucleus to be effective. For 
this reason, antibodies labeled with auger-emitting radionuclides need to target the entire 
tumor cell population for efficient therapy (Cornelissen & Vallis,  2010). 
9. Improving the properties of antibody in radioimmunoscintigraphy and 
radioimmunotherapy 
Several investigations using different radionuclides, engineered antibodies and methods to 
increase antibody accumulation and penetration are currently being evaluated and have so 
far shown promising results. The main properties of antibodies that have been manipulated 
to optimize efficacy are size, immunogenicity, affinity and avidity. 
9.1 Size 
Size is a factor that impacts the circulation time of antibodies. IgG antibodies are large 
proteins with a molecular weight of 150 kDa which limits the diffusion of the antibodies 
from the blood into the tumor, resulting in a heterogeneous intratumoral distribution. 
Furthermore, IgG antibodies are characterized by a long circulatory half-life in plasma for 
three to four days. Due to this slow clearance from the blood, tumor-to-background ratio is 
usually low. The primary concern for using radionuclide labeled IgG is that it remains in the 
blood for an extended period of time which continually exposes the highly sensitive red 
marrow to radiation resulting in dose-limiting myelosuppression. While intact mAbs are 
primarily catabolized by the liver and spleen, mAb fragments are mainly excreted via the 
kidneys, thereby increasing uptake in the kidneys and lead to increase consequently the 
kidney absorbed radiation dose. (Koppe et al., 2005). If radiometals are used as the 
radiolabel, they will accumulate in the hepatic parenchyma. The large size of an antibody 
impacts its ability to move through a tumor mass.  The smaller forms of  antibodies such as 
F(ab')2 or Fab fragments and more recently, molecularly engineered antibody subfragments 
with more favorable pharmacokinetic properties, are removed more rapidly from the blood, 
thereby improving tumor/blood ratio. There have been reports of improved therapeutic 
responses using smaller-sized antibodies, but these smaller entities frequently are cleared 
from the blood by renal filtration and as a result many radionuclides (eg, radiometals) 
become trapped in a higher concentration in the kidneys than in the tumor. Changes in the 
molecular size/structure of the IgG can also alter the normal tissue distribution, shifting 
uptake from the liver to the kidneys (Sharkey & Goldenberg, 2009). Reducing the size of 
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antibody below the filtration threshold of kidneys (70 kDa), increases renal excretion and 
therefore decreases toxicity to this organ. Hence, being smaller molecules, antibodies are 
more suited to RIT and RIS with short circulation time, lower absolute localisation to the 
tumor and rapid excretion by the kidneys (Yazaki et al., 2001).  
9.2 Immunogenicity 
The first mAbs being investigated for RIS and RIT were murine antibodies which can 
provoke an immune response in human beings. HAMA inactivate and eliminate murine 
antibodies after repeated administration. The formation of antibody-HAMA complexes also 
leads to the allergic-like HAMA response. In this way, therapeutic benefit of murine mAbs 
is limited by their side effect profile, short serum half-life and inability to trigger human 
immune effector functions. In order to reduce the immunogenicity of antibodies, chimeric 
antibodies were designed by combining constant domains of human antibodies with 
variable regions of murine antibodies (Carlssona et al., 2003). However, chimeric mAbs 
minimize the immunogenic content, trigger the immunologic efficiency and allow a 
prolonged serum half-life in comparison with murine mAbs. As a further advancement of 
chimeric mAbs, in 1986, Jones first reported the production of humanized monoclonal 
antibodies (Jones et al., 1986). Humanized antibodies are almost completely of human origin 
with only the complementarity determining regions (CDRs) being murine. To completely 
avoid the risk of immunogenicity, further developments have led to the production of fully 
human antibodies that contain 100% human proteins. For the development of fully human 
mAbs, phage display technology and genetically engineered mice are the key techniques 
that have been widely used to link genotype and phenotype. Immunosuppressive agents 
have been investigated to reduce HAMA. Low-dose cyclosporin, as used with a highly 
immunogenic antibody, was unable to significantly reduce HAMA following murine CC49 
delivery. Thus, cyclosporin may have some efficacy in reducing immunogenicity of murine 
antibodies in patients, but does not appear to be sufficient to permit administration of 
multiple doses in all patients (Pagel, 2009). 
9.3 Affinity and avidity 
The antibody affinity is a measure of the strength of binding of an individual antibody binding 
site to a single antigenic site. This can be considered as the sum of all the non-covalent 
interactions between antibody and antigen involved in the binding reaction. However, 
antibody molecules usually have more than one binding site and many antigens contain more 
than one antigenic site and therefore multivalent binding may be possible. The strength with 
which a multivalent antibody binds to an antigen, is termed avidity. Although high affinity is 
a requirement for good tumor localization, there seems to be a point at which further increases 
in affinity do not increase uptake at the target site (Schlomet al., 1992; Colcher et al., 1988). 
Indeed, reduced tumor uptake and limitations on penetration of antibody into the tumor 
tissue can result from the increasing of antibody affinity (Dearling & Pedley, 2007). 
10. Technical limitations of radioimmunoscintigraphy and 
radioimmunotherapy 
Although this conceptually simple technique has been investigated and refined for almost 50 
years, it still has inherent limitations. In the present part, the problems of imaging and therapy 
of breast cancer by radioimmunoscintigraphy and radioimmnotherapy methods are discussed.  
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10.1 Antibody 
Monoclonal antibodies have inherent limitations for application in targeting methods of 
imaging and therapy that can be cited in followings: 
• mAbs are large molecules and so have difficulty in penetrating to large tumor masses 
especially in the early stages of the malignancies (Sergides et al., 1999). 
• mAbs are currently not entirely sensitive for malignant tissues. For example, mAb B72.3 
recognizes TAG-72 and has been used extensively for the detection of several 
malignancies including breast, lung, ovary and colorectal (Granowska et al., 1991).  
10.2 Antigen 
Tumors produce a chaotic vascular system in which blood flow is slow and can be 
interrupted or even reversed. The ratio of tissue cells to vascular support is lower than most 
normal tissues. These effects create areas of tumor hypoxia which are relatively resistant to 
radiation therapy and therefore reduce the efficacy of RIT (Sergides et al., 1999). Some 
antigens of breast cancer are epithelial surface antigens lying on the inner surfaces of cells, 
thus being exposed to the circulation only by neoplastic architectural disruption. Other 
factors influencing the suitability of antigens for tumor targeting are internalization and 
shedding into the bloodstream. Unfortunately, the majority of identified antigens in human 
tumors represent tumor-associated antigens, not only present on the tumor tissues, but also 
detectable on normal tissues (Sergides et al., 1999). 
10.3 Background radioactivity 
A high background level of radiation due to the presence of radioactivity in normal tissues 
reduces the tumor/background  ratio which reduces the success of diagnosis and therapy. 
Tumor/background ratio may be diminished by the following factors: (1) the relative long 
circulation time of nonlocalized murine immunoglobulin in human beings; (2) binding of 
radiolabeled antibodies to antigens, released by the tumor in the blood pool; (3) the presence 
of free radionuclides and the subsequent accumulation in kidneys, bladder and other 
tissues, (4) non-specific uptake antibody by binding Fc fragment of antibody to normal 
tissues; (5) phagocytosis of murine immunoglobulin especially in the liver; (6) the presence 
of immune complexes due to the reaction of labelled antibody with Fc cell surface receptors, 
if non-fragmented immunoglobulins are used and (7) unconjugation of radio-isotope from 
antibody in the patient body (Sergides et al., 1999). 
11. Improving in radioimmunoscintigraphy and radioimmunotherapy 
techniques 
A variety of methods have been developed to counter the inherent flaws in RIS and RIT 
techniques. The following section discusses the methods for overcoming these problems. 
11.1 Pre-targeting 
The pretargeting procedure was developed from the concept that the targeting antibody 
should be separated from the targeting radionuclide through the use of a bispecific antibody 
(Chang et al., 2002). An alternative approach to improve tumor:blood ratio for RIS is the use of 
pre-targeting strategies. The pre-targeting strategies have led to significant improvements in 
T/B ratio and better diagnostic imaging (Dearling & pedley, 2007). Also, pretargeting has been 
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applied successfully for radioimmunoimaging, because the pretargeted antibody is nontoxic. 
High doses can be administered to saturate antigenic sites at the tumor. Pretargeting strategies 
for RIT have been applied to achieve higher intratumor concentration of isotope than achieved 
by conventional RIT (Kraeber–Bodere et al., 2009). The simplest form of pre-targeting is to use 
a second antibody reagent to clear blood background activity, hence improving the 
signal:noise ratio and the quality of the image. Immune complexes formed by a second 
antibody are rapidly removed from the circulation by the reticuloendothelial system, 
particularly in the liver. In the alternative approach, the administration of antibody and 
radiolabel are separated. Antibody is allowed to localize to the tumor and sufficient time is 
allowed for antibody clearance from the blood and non-target tissues (Dearling & pedley, 
2007). Radioisotope is then injected separately in a form which can be readily captured by the 
tumor bound antibody. The approaches using streptavidin/biotin binding systems raised 
much interest, because the affinity of streptavidin for biotin is exceptionally high (Gruaz-
Guyon et al., 2005). In this strategy, the high affinity of the avidin:biotin system is used to 
capture radiolabeled small molecules from the blood as a two-step imaging method. 
Antibody-avidin conjugate is injected and allowed to be localized to the tumor and cleared 
from the blood (Dearling & pedley, 2007). Radioactive avidin is then injected which localizes 
the tumor by taking advantage of the high affinity and specificity of avidin for biotin (Roland 
et al., 2010, Dearling & pedley, 2007).  
11.2 Dose fractionation 
Dose fractionation has been proposed as a method to improve the therapeutic effect of 
radioimmunotherapy (Dearling & pedley, 2007, Denardo et al., 2002). Fractionated 
radioimmunotherapy may improve therapeutic outcome by decreasing heterogeneity of the 
dose delivered to the tumor and by decreasing hematologic toxicity, thereby allowing an 
increased amount of radionuclide that can be administered (Linden et al,. 2005) . A variety 
of fractionation regimens have been developed and the studies have reported both against 
and in its favour (Goel et al., 2001; Buchsbaum et al., 1995; Pedley et al., 1993; Schlom et 
al.,1990; Beaumier et al., 1991). This technique has several advantages including more 
uniform distribution of mAb and radiation dose, patient-specific radionuclide and radiation 
dose, control toxicity by titration of an individual patient, reduced toxicity, increased tumor 
radiation and efficacy and prolongation of tumor response (Violet, 2008). This technique has 
some disadvantages including lower radiation dose rate, complex strategy to implement, 
treatment interruption, increased cost and potential delay in tumor regression (Dearling & 
pedley, 2007).  
11.3 Delayed imaging 
Kinetic differences in specific and non-specific uptake of radioactivity provide an 
opportunity to image at a time when the T/B ratio is optimal. Background radioactivity falls 
with time due to excretion and decay of the radioisotope. Tumor radioactivity also falls with 
time, but not as fast as the background. The optimum time for RIS is dependent on the 
selected antibody and radioisotope and detection method (Sergides et al., 1999).  
11.4 Background subtraction 
If the background is labeled using a non-specific antibody, the background signal can then 
be subtracted from the results of RIS (Sergides et al., 1999; Goldenberg et al., 1978). It should 
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be remembered that this technique leads to increase the total dose of radioactivity in the 
patient body that leads to undesirable side effects. 
11.5 Pre-scouting  
In the latter application, RIS is performed as a scouting procedure prior to RIT to enable the 
confirmation of tumor targeting and the estimation of radiation dose delivered to both 
tumors and normal tissues. For this purpose, the radioimmunoconjugates used for RIS and 
RIT should demonstrate a similar biodistribution and therefore radionuclides with 
comparable chemical properties have to be chosen (Dearling & pedley, 2007). When using 
131I for RIT, both 123I and 131I can be used for a RIS scouting procedure. When using 90Y 
for RIT, 111In can be used to represent this pure beta-emitter (Dearling & pedley, 2007). 
Finally, when aiming the therapeutic use of 186Re or 188Re, either these radionuclides 
themselves can be used for an imaging procedure or 99mTc (Pontus et al., 2004). 
11.6 Increasing the dose delivery  
The result of experiments indicated that increasing the dose of antibody will increase the 
amount of radioactivity in the tumor (Begent et al., 1987). On the other hand, this technique 
has side effects due to HAMA response against the dramatic rise in dose of administered 
antibody that limits the application of this technique (Dearling & pedley, 2007). 
11.7 Combined imaging systems 
The resolution of latest-generation of PET and SPECT cameras has been improved and the 
combination of these systems with an integrated CT (and also MRI) has led to a much better 
interpretation of the data (Dearling & pedley, 2007). In addition, the indirect combination of 
nuclear imaging and optical imaging systems can also serve shared purposes (Munnink et 
al, 2009). 
11.8 Second antibody 
The background counts can be reduced by removing radioactivity from the circulation. This 
can be achieved by the use of a second antibody active against the RIS antibody. In this 
technique, after the binding time of original antibody to tumor tissue, the second antibody 
administers to the patient (Sergides et al., 1999). The second antibody binds to the 
radioactive antibody that remains in the blood stream. The reticuloendothelial system 
uptakes antibody-antibody complex and leads to concentrate radioactivity in liver and 
spleen. This technique leads to increase in T/B ratio without adverse effects. The only 
disadvantage of this method is limitation in the detection of metastases at liver and spleen 
(Sergides et al., 1999).  
11.9 Improving the internalization of the radiolabeled mAb 
One significant factor that influences the absorbed radiation dose to the tumor is the fate of 
the radiolabel after internalization of the radiolabeled mAb into the tumor cells. In case of 
internalisation, the radionuclides will come closer to the critical radiation target, i.e. nuclear 
DNA. Internalization of the antibody depends on various factors including the antibody, the 
targeted antigen and the tumor cells. On the other hand, internalisation might be 
disadvantageous, if it leads to quick degradation of the targeting agent followed by diffusion 
and elimination of the radionuclide (Boswell et al., 2007). Most antibodies including those 
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that target antigens located on the surface of the tumor cells such as anti-CEA antibodies, are 
eventually catabolized. Intracellular degradation of the targeting agent can be prevented by 
e.g. dextranation (Bue et al., 2000). Radiolabeling of antibodies with 90Y or 177Lu is 
performed by linking these radionuclides to chelators (DTPA or DOTA) which are chemical 
moieties that complex free metal ions. These chelators are conjugated to the antibodies and 
subsequently to the radiolabel. After catabolization of mAbs labeled with 90Y- or 177Lu-
DTPA/-DOTA, the catabolic products are conjugated to, in most cases, lysine (e.g. 90Y- or 
177Lu-DOTA-lysine). Whereas radioiodinated tyrosine is excreted by the cell, the 90Y- or 
177Lu-DTPA/DOTA-lysine metabolites are trapped within the lysosomes, thereby increasing 
the tumor retention time of these radiolabels (Koppe et al., 2005). Cellular excretion can also 
be limited if the radionuclides are of metal type, e.g. indium or yttrium, and this is due to 
intracellular retention of metal containing catabolic products (Press et al., 1996). 
11.10 Targeting agents 
RIS may be improved by the production of superior targeting agents to deliver radioactivity 
to tumor sites. For example, instead of using intact antibodies to target tumors, fragments of 
antibodies retaining their antigenic specificity can be used (Sergides et al., 1999). Fragments 
of an antibody have several advantages including: 
1. Shorter circulating half-life and faster execration by kidney that leads to decrease 
background signals. 
2. Smaller molecular weight that leads to faster and more deeply diffuse into tumors. 
3. Reduce non-specific antibody binding by Fc receptor on cells due to the loss of the Fc 
fragment  
4. Reduce the HAMA response due to the loss of Fc fragment that is responsible for 
immune response to foreign proteins. 
Further improvements in the structure of antibodies are being explored with antibody 
engineering technology. Single-chain antigen binding fragments (sF7) consisting of variable 
heavy (VH) or variable light (VL) domains and recombinant sF7 peptides which are VH and 
VL domains connected by peptide linkers are the productions of this technology. These 
productions has high affinity for antigen (Sergides et al., 1999). 
11.11 Antibody affinity 
The strength of the antibody:antigen interaction is measured through the binding affinity 
and is quantified through the association constant (Ka) (Boswell et al., 2007). Increasing Ka 
of antibody will be leads to an increase in uptake antibody in the tumor. However, they may 
be less able to penetrate deeply due to strongly bound at the tumor surface. The studies with 
iodine radiolabeled scFvs demonstrated that a threshold affinity between 10−7 and 10−8 M 
was required to observe detectable tumor uptake in mice 24 h post injection, whereas no 
gain in tumor accumulation was observed with affinities >10−9 M. Affinities >10−9 M were 
detrimental to rapid and uniform tumor penetration due to stable binding at the first pass of 
tumor antigens forming a binding site barrier (Adams et al., 2001). 
11.12 Multivalency 
Multivalency has been reported as an advantage in radioimmunotherapy (Dearling & pedley, 
2007). Conversion of monovalent antibodies into multivalent format increases their functional 
affinity and decreases dissociation rates for cell-surface and optimizes biodistribution 
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(Dearling & pedley, 2007). In addition, it allows the creation of bispecific antibody molecules 
that can target two different antigens simultaneously (Sergey et al., 2008). During the last 
decade, several techniques in multivalency engineering have been developed. Each of these 
strategies proposed to link monovalent domains and to produce multivalent antibody, 
obviously has some advantages in some special cases, but none of them is universal. The 
advantages of tumor targeting with multivalent antibody derivatives have been investigated 
for scFv dimers, prepared as disulfide-linked dimers of scFv (Adams et al., 1995), non-covalent 
diabodies (Kortt et al., 2001) and some other bi(multi)valent variants of recombinant antibody 
fragments (Kubetzko et al.,2006; Shahied et al., 2004; Willuda et al., 2001). In most cases, 
dimeric/divalent antibodies showed significant improvement of their pharmacokinetics and 
biodistribution over monomers (Sergey et al., 2008). 
11.13 CockTails 
One problem of RIS is the existence of diversity of epitopes on surface tumor cells that 
reduces uptake radioactivity in tumor. An alternative approach to improve the uptake of 
radioactivity by the target is using cocktails of several radiolabelled antibodies that 
recognize different epitopes or antigens on the same tumor. However, some of the 
experiments indicated positive results by using cocktails, other experiments showed that the 
mAbs of cocktails competed to bind to epitopes with each other and reduce the efficacy of 
the mixture to less than that of one antibody used alone (sergey et al., 2008).  
11.14 Increasing tumor uptake  
By increasing the level of antigen expression, diagnosis and therapy based on targeting can 
be improved. For example, hyperthermia can increase the amount of presenting antigen in a 
tumor (Wilder et al., 1993). Furthermore, several cytokines such as interferon alpha and 
interleukin-6 have been found to upregulate the expression of cell surface antigens 
including histocompatibility antigens and tumor associated antigens such as 
carcinoembryonic antigen (CEA). In both in vivo and in vitro studies an improved antibody-
uptake has been demonstrated as a result of the administration of vasoactive peptides and 
cytokines such as IL-2 or external beam radiation therapy may result in a specific increased 
vascular permeability at the tumor site and thus an increased antibody uptake (Guadagni, et 
al., 1990). Structural modification (e.g., PEGylation) and residue mutation are both useful 
strategies in reducing chemically or physically derived nontarget organ uptake of Abs, but 
these methods do not reduce the uptake due to receptor expression within nontarget organs. 
These are research areas of high interest (Boswell & Brechbiel, 2007). 
11.15 Reducing kidney uptake 
Elevated renal uptake and prolonged retention of radiolabeled antibody is a problem in the 
therapeutic application of such agents (Dearling & pedley, 2007). Because of the negative 
charge of the basement membrane of the glomeruli, positively charged catabolites of the 
radiopharmaceutical may be retained in the kidney, increasing the toxic absorbed dose to 
this radiosensitive organ (Dearling & pedley, 2007). The result of some studies 
demonstrated that lysine, histidine and arginine were effective in reducing the renal uptake 
of radiopharmaceutical and lysine was the most effective (Lin et al., 2007). In these studies it 
has been shown that renal retention can also be minimized by the administration of lysine, a 
cationic amino acid, whereas the uptake in all other organs as well as the tumor remains 
unaffected (Behr et al., 1995). 
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12. Conclusion 
In recent years, significant developments in the application of targeted imaging and therapy 
have taken place in nuclear medicine. This chapter suggests that optimization of 
radioimmunoscintigraphy and radioimmunotherapy methods is still possible and 
emphasizes that these technologies are continuing to progress and are close to become 
routine modalities in the identification of breast cancer sites and its therapy. The 
development of effective imaging and therapy of breast cancer relies to a great extent on the 
development of effective carriers and target agents that can deliver radionuclids to the 
cancer cells. These agents should be able to carry a large load of radionuclids and selectively 
deliver them to the cancer cells with high accuracy to achieve effective cancer cells death 
without inducing nonspecific toxicity. This means that the use of new targeting agents such 
as peptides and affibodies can provide promising results. Liposomes, dendrimers, micelles 
and nanoparticles present large families of carriers that can be exploited for delivery of 
radionuclids and they can be further improved to diagnose and therapy of breast cancer in 
the future. The research in the field of targeted imaging and therapy will help us to avoid 
unnecessary costs and potentially allow these new methods to be available for the majority 
of patients who need them, leading to better quality and quantity of life. 
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